热门资讯> 正文
IO Biotech Gets Data Monitoring Committee Recommendation to Continue Phase 3 Melanoma Study
2024-08-31 04:34
04:34 PM EDT, 08/30/2024 (MT Newswires) -- IO Biotech (IOBT) said Friday that an Independent Data Monitoring Committee has recommended the continuation of its late-stage trial of vaccine candidate IO102-IO103 in combination with Merck's (MRK) Keytruda as a first-line treatment for patients with unresectable or metastatic melanoma.
No new safety signals were observed at interim analysis, the clinical-stage biopharmaceutical company said. The primary endpoint of progression-free survival is projected to be reached in the first half of 2025.
Price: 1.4400, Change: -0.06, Percent Change: -4.00
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
